Arena Pharmaceuticals Inc., F. Hoffmann-La Roche AG, and GlaxoSmithKline plc are three key vendors highlighted in a new Technavio report
London, 27 July 2015 – Technavio has published a new report on the anti-obesity drugs market in the US, which is expected to grow at a CAGR of more than 29% from 2015-2019.
Anti-obesity drugs market segmentation including drug class, medication type, and geography
Technavio’s report analyses the solutions and products offered by market vendors and presents a comprehensive breakdown in terms of market segmentation for different classes of drug, including peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs.
Additionally, analysts have segmented market projections by key geography, and also by medication type, focusing on monotherapies and polytherapies.
“Anti-obesity drugs must fulfil certain stringent regulatory parameters in order to obtain approval. The food and drug administration has established guidelines regarding the mandatory efficiency and safety studies required for these drugs,” says Faisal Ghaus, Vice President of Technavio.
Anti-obesity drugs: Market scope and calculation of market size
This report covers the present scenario and growth prospects for the anti-obesity drugs market in the US from 2015-2019. To calculate the market size, we use the revenue generated from the sales of currently approved and patented drugs, generics, and OTC products for the treatment of obesity.
Industry analysis includes:
Key Vendors:
- Arena Pharmaceuticals Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Novo Nordisk A/S
- Orexigen Therapeutics Inc.
- Vivus Inc.
Market Growth Drivers:
- Increased Prevalence of Obesity
- Presence of High Unmet Needs
Market Challenges:
- High Trial Attrition Rates
- Dominance of Alternative Therapies
Market Trends:
- Stringent Regulatory Policies
- Uptake of Polytherapies
View the anti-obesity drugs market in the US report.
https://www.technavio.com/%3Cp%3E%3Cstrong%3E%3Ca%20href%3D%22http%3A//ww…
